Vericel Scientific Publications & Presentations

Key publications, presentations and abstracts of Vericel Corporation are listed in chronological order below and available for download in PDF.

Journal Articles

The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy 

Timothy D. Henry, MD, FACC on behalf of Arshed A. Quyyumi, Gary L. Schaer, David R. Anderson, Catalin Toma, Cara East, David P. Recker, Ann Remmers, James Goodrich, Amit N. Patel and the ixCELL-DCM Investigators

Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial

Amit N Patel*, Timothy D Henry*, Arshed A Quyyumi, Gary L Schaer, R David Anderson, Catalin Toma, Cara East, Ann E Remmers, James Goodrich, Akshay S Desai, David Recker, Anthony DeMaria, for The ixCELL-DCM Investigators

The iXCELL-DCM Trial: Rationale and Design

Timothy D. Henry, Gary L. Schaer, Anthony DeMaria, David Recker, Ann E. Remmers, James Goodrich, Amit Patel. CT-1575 Cell Transplantation early e-pub; March 21, 2016.

Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy

Timothy D. Henry, Jay H Traverse, Baron L. Hammon, Cara A. East, Brian Bruckner, Ann E. Remmers, David Recker, David A. Bull, and Amit N. Patel. Circulation Research, August 20, 2014.

Safety and Efficacy of Ixmyelocel-T, An Expanded, Autologous Multi-Cellular Therapy, Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases

Kelly J Ledford, Nikki Murphy, Frank Zeigler, Ronnda L Bartel and Ross Tubo. Stem Cell Research & Therapy (2015) 6:25

Stem Cell Therapy for Craniofacial Bone Regeneration: A Randomized, Controlled Feasibility Trial

Darnell Kaigler, Giorgio Pagni, Chan Ho Park, Thomas M. Braun, Lindsay A. Holman, Erica Yi, Susan A Tarle, Ronnda L. Bartel, William V. Giannobile.  Cell Transplantation, Vol 22, 2013

From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastroms Ixmyelocel-T

Ronnda L. Bartel, Erin Booth, and Caryn Cramer. Stem Cell Rev and Rep, March 2013.

The Aastrom Experience

Ronda L Bartel, Caryn Cramer, Kelly Ledford, Amy Longcore, Christopher Parrish, Theresa Stern, Sharon Watling, and Frank Zeigler. Stem Cell Research & Therapy, July 2012.

Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial

Richard J Powell, William A Marston, Scott A Berceli, Raul Guzman, Timothy D Henry, Amy T Longcore, Theresa P Stern, Sharon Watling and Ronnda L Bartel. Molecular Therapy, March 2012.

Safety and Efficacy of Ixmyelocel-T, An Expanded Patient-Specific Mixed Cell Product, in Dilated Cardiomyopathy (IMPACT-DCM)

Brian Bruckner, Amit N. Patel, Baron L. Hamman, Omar M. Lattouf, Nicholas G. Smedira, Ronnda L. Bartel, and Sharon Watling. International Society for Heart and Lung Transplantation, November 2011.

Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia

Richard J. Powell, MD, Anthony J. Comerota, MD, Scott A. Berceli, MD, Raul Guzman, MD, Timothy D. Henry, MD, Edith Tzeng, MD, Omaida Velazquez, MD, William A. Marston, MD, Ronnda L. Bartel, PhD, Amy Longcore, MS, Theresa Stern, PhD, and Sharon Watling, PhD. Journal of Vascular Surgery, June 2011.

Upper Extremity Ischemia Treated with Tissue Repair Cells from Adult Bone Marrow

A. Comerota, A. Link, J. Douville, E. Burchardt. Journal of Vascular Surgery, Published online June 24, 2010.

Single-Pass, Closed-System Rapid Expansion of Lymphocyte Cultures for Adoptive Cell Therapy

J.A. Klapper, A.A. Thomasian, D.M. Smith, G.C. Gorgas, J.R. Wunderlich, F.O. Smith, B.S. Hampson, S.A. Rosenberg, M.E. Dudley. Journal of Immunological Methods, Vol. 345(1-2): 90-99, 2009.

Proteomic Characteristics of ex vivo-Enriched Adult Human Bone Marrow Mononuclear Cells in Continuous Perfusion Cultures

A.K. Prahalad, J.H. Hock. Journal of Proteome Research, Vol. 8(4): 2079-2089, 2009.

Large-Scale Production of Adult Stem Cells for Clinical Use

K. Goltry, B. Hampson, N. Venturi, R. Bartel. “Emerging Technology Platforms for Stem Cells.” John Wiley & Sons, Inc., Chapter 9: 153-168, 2009.

Manufacturing Patient-Specific Cell Therapy Products – An Overview and Case Study of Tissue Repair Cell Technology

B. Hampson, J. Rowley, N. Venturi. BioProcess International, Vol. 6(8): 60-72, 2008.

Tissue Repair Cells for the Treatment of Cardiovascular Diseases

K. Goltry, J. Rowley, M. Peters, E. Burchardt. Advances in Molecular Medicine, Vol. 3(1): 5-13, 2007.

Good Manufacturing Practice-Compliant Expansion of Marrow-Derived Stem and Progenitor Cells for Cell Therapy

M.H. Gastens, K. Goltry, W. Prohaska, D. Tschöpe, B. Stratmann, D. Lammers, S. Kirana, C. Götting, K. Kleesiek. Cell Transplantation, Vol. 16(7): 685-696, 2007.

Presentations & Posters

Ixmyelocel-T, A Unique Mixed Cellular Therapy for the Treatment of Vascular Diseases Associated with Endothelial Dysfunction

KJ Ledford, EN Murphy, F Zeigler, RL Bartel,  AHA Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, May 2013

Phase 3 Readiness for Autologous Cell Therapies: Unique Software Applications for Training, Scheduling and Manufacturing of Ixmyelocel-T

N. Venturi, B. Hampson, S. MacKay, and R. L. Bartel.  International Society for Cellular Therapy 19th Annual Meeting, April 2013

Effects of Ixmyelocel-T on Murine Bleomycin-Induced Lung Fibrosis

Erin A. Booth, F Zeigler, Sem Phan, and R. L. Bartel.  International Society for Cellular Therapy 19th Annual Meeting, April 2013

Evidence for the Beneficial Effects of Ixmyelocel-T in the Treatment of Critical Limb Ischemia

KJ Ledford, EN Murphy, F Zeigler, RL Bartel. Arteriosclerosis, Thrombosis and Vascular Biology, April 2012.

Ixmyelocel-T Therapy Alternatively Activated Macrophages Potentially Exert Atheroprotective Effects

KJ Ledford, C Parrish, F Zeigler, RL Bartel. Keystone Symposia on the Molecular Basis of Vascular Inflammation and Atherosclerosis in Big Sky, Montana, starting Sunday, March 2012.

Safety and Efficacy of Ixmyelocel-T, A Patient-Specific Expanded Multicellular Therapy, in Dilated Cardiomyopathy

Timothy D. Henry, Jay H. Traverse, Rod Badger, Marco Costa, Patricia Mitchell, Kristen Kolsch, Ronnda L. Bartel, Sharon Watling, Amit N. Patel. Society for Cardiovascular Angiography and Interventions (SCAI), May 2012.

IMPACT-DCM 12 Month Study Update

Brian Bruckner, MD. International Society for Heart & Lung Transplantation (ISHLT), April 2012.

Leadership in Regenerative Medicine

Tim Mayleben. World Stem Cells & Regenerative Medicine Congress, May 2012.

Interim Analysis Results Impact DCM-Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients with Heart Failure Due to Dilated Cardiomyopathy

Amit Patel, MD, MS. International Conference on Cell Therapy for Cardiovascular Disease (IC3D), January, 2011

Aastrom Presents Results From Two Studies of Autologous Bone Marrow-Derived ixmyelocel-T at the International Society for Cellular Therapy Meeting

1.) Autologous Bone Marrow-Derived Cells (Ixmyelocel-T) Contain Mesenchymal Stem Cells Expressing B7H3 and Modulate Immune Response In Vitro

F. Zeigler, C. Parrish, J. Osborne, A. Wong, P. Kulasekaran, and R. Bartel. International Society for Cellular Therapy, May 2011.

2.) Autologous Tissue Repair Cells from Bone Marrow Require MAC-1 Integrin Function for Expansion of Both Hematopoietic Cells and Mesenchymal Stem Cells

J. Osborne, K. Ledford, C. Parrish , A. Wong, F. Zeigler, and R. Bartel. International Society for Cellular Therapy, May 2011.

Safety and Efficacy of Ixmyelocel-T, an Expanded Patient-Specific Mixed Cell Product in Dilated Cardiomyopathy (IMPACT-DCM)

Amit N. Patel, Baron L. Hamman, Brian Bruckner, Omar M. Lattouf, Nicholas G. Smedira, Cara East, David A. Bull; Ronnda L. Bartel, Sharon Watling. HFSA Annual Meeting, September, 2011.

Patient-Specific Cellular Therapy (Ixmyelocel-T) is Safe and Improves Time to Treatment Failure in Patients with Critical Limb Ischemia and No Revascularization Options

William Marston, MD. American Heart Association Scientific Sessions, November 2011.